ABIONYX Pharma SA (0RAG.L)
LSE · EUR
€1.62 (-0.61%) as of
Key statistics
- EPS (TTM)
- -0.1480
- 52-week range
- 1.0400 – 2.3200
- Beta
- 0.47
- Revenue (TTM)
- 4.06M
- Profit margin
- -136.60%
- Volume
- 30.00
About ABIONYX Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase (LCAT) deficiency, as well as in a Phase II trial for the treatment of sepsis. It is also developing ABNX-100, a strategic extension into ophthalmology of CER-001 that is in preclinical trial for the treatment of uveitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was incorporated in 2005 and is headquartered in Balma, France.
- Headquarters
- Balma, France
- Employees
- 49
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.
Related stocks
- Partners Group Private Equity L (PEYL.XC)
- MEDISTIM ASA MEDISTIM ORD SHS (0OCD.L)
- ELIOR GROUP ELIOR GROUP ORD SHS (0QVP.IL)
- PENTAIR PLC PENTAIR ORD SHS (0Y5X.L)
- DBV TECHNOLOGIES SA DBV TECHNOL (0QAJ.IL)
- COPART INC COPART ORD SHS (0ACI.L)
- TECHNOGYM SPA TECHNOGYM ORD SHS (0RG1.IL)
- HAPAG LLOYD AG HAPAG LLOYD ORD (0RCG.IL)